Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study.

Yuichiro KikawaTakeshi KotakeShigeru TsuyukiYookija KangSachiko TakaharaYuri FujimotoHiroyasu YamashiroHiroshi YoshibayashiMasahiro TakadaRie YasuokaKatsuhiko NakatsukasaKazuhiko YamagamiHirofumi SuwaToshitaka OkunoIchiro NakayamaTatsushi KatoNobuko OguraYoshio MoriguchiHiroshi IshiguroTatsuo KagimuraTetsuya TaguchiTomoharu SugieMasakazu Toi

Published in: Breast cancer (Tokyo, Japan) (2022)

This study is registered with Clinical Trials.gov (NCT 02,551,263).

Keyphrases

metastatic breast cancer
randomized controlled trial
squamous cell carcinoma
radiation therapy
phase ii
locally advanced
open label